2018-11-27| In-DepthR&DTechnology

Halting C.difficile with first-in-class oral enzyme & microbiome

by GeneOnline
Share To

By Ajay V. Patil

Clostidium difficile – A serious healthcare associated infection

Clostridium difficile infection is a threatening infection (453,000 infections and close to 29,000 deaths in the United States each year) and it is associated with commonly used intravenous (IV) beta-lactam antibiotic treatment. Beta-lactam antibiotics are often the treatment of choice for hospitalized patients with infections; they include commonly used penicillin and cephalosporin antibiotics (like ceftriaxone). These antibiotics can cause harmful effects in the intestinal tract especially disturbing the gut microbiome which is important for prevention of C.difficile infection.

SYN004 – Fighting infection by protecting healthy microbiome

SYN-004 (ribaxamase) is an oral β-lactamase designed to be coadministered with intravenous antibiotics. It is developed by Synthetic Biologics Inc., a company focused on therapeutics benefiting through preserving healthy microbiome. Ribaxamase reportedly degrades excess-lactam antibiotic present in the small intestine. This results in keeping the natural balance of the gut microbiome intact to prevent C.difficile infection, other antibiotic-associated diarrheas, pathogenic overgrowth and the development of antimicrobial resistance (AMR).

Phase I and phase IIa studies

Phase I clinical studies showed that, ribaxamase was well tolerated compared to a placebo group and displayed negligible systemic absorption. In order to confirm the mechanism of action (β-lactam degradation in small intestine) phase IIa clinical studies were performed in subjects with functioning ileostomies (allowing serial sampling of their intestinal chime). Ribaxamase showed near complete degradation of ceftriaxone (below the level of quantitation) in the intestines of all subjects in both phase I & IIa studies. Coadministration of oral ribaxamase with intravenous ceftriaxone did not change plasma levels of ceftriaxone. Activity of this pH-dependent, delayed-release formulation of ribaxamase was not hampered in the presence of the proton pump inhibitor esomeprazole as shown in another coadministration study.

Positive phase III talks with FDA

Synthetic Biologics Inc. recently announced successful completion of an End-of-Phase II meeting with the U.S. FDA to discuss development of SYN-004 (ribaxamase) as the prophylactic for antibiotic-mediated C.difficile infection. FDA has proposed criteria for Phase III clinical efficacy and safety. If achieved, FDA may support its submission for marketing approval on the basis of a single Phase III clinical trial. Although final agreement is contingent on FDA evaluation of a detailed Phase III clinical trial protocol.

Development of such efficient prophylactic therapies which work through healthy microbiome preservation will provide new hope against serious and emerging infections around the globe.


  2. under NCT02419001 and NCT02473640


© All rights reserved. Collaborate with us: [email protected]
Related Post
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
Advancements in Alzheimer’s Disease Drug Innovation and Funding Programs in 2024
FDA Greenlights Eli Lilly’s Groundbreaking Alzheimer’s Drug Kisunla for Early Symptomatic Treatment
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
Assessment of Supply Chain Risk Key to Improving Medicine Access
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
Scroll to Top